Keytruda (pembrolizumab) vs Lunsumio (mosunetuzumab-axgb)
Keytruda (pembrolizumab) vs Lunsumio (mosunetuzumab-axgb)
Keytruda (pembrolizumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which can help the immune system detect and fight cancer cells, and is widely used in various types of cancers, including melanoma, non-small cell lung cancer, and head and neck cancers. Lunsumio (mosunetuzumab-axgb), on the other hand, is a bispecific T-cell engager that redirects the body's own T-cells to engage and eliminate B-cells, and is used specifically for the treatment of certain types of B-cell non-Hodgkin lymphoma. When deciding between Keytruda and Lunsumio, it is crucial to consider the specific type of cancer being treated, the patient's overall health, and the treatment's side effect profile, as well as consulting with a healthcare professional who can provide personalized advice based on the patient's unique medical situation.
Difference between Keytruda and Lunsumio
| Metric | Keytruda (pembrolizumab) | Lunsumio (mosunetuzumab-axgb) |
|---|---|---|
| Generic name | Pembrolizumab | Mosunetuzumab-axgb |
| Indications | Various types of cancers including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others | Follicular lymphoma |
| Mechanism of action | Programmed death receptor-1 (PD-1) blocking antibody | Bispecific antibody targeting CD20 on B cells and CD3 on T cells |
| Brand names | Keytruda | Lunsumio |
| Administrative route | Injection (Intravenous) | Injection (Intravenous) |
| Side effects | Fatigue, musculoskeletal pain, decreased appetite, itching, diarrhea, nausea, rash, fever, cough, dyspnea, constipation, pain in extremity, and headache | Cytokine release syndrome, infections, fatigue, diarrhea, musculoskeletal pain, and anemia |
| Contraindications | Individuals with hypersensitivity to pembrolizumab or any of its excipients | Individuals with hypersensitivity to mosunetuzumab-axgb or any of its excipients |
| Drug class | Anti-PD-1 monoclonal antibody | Bispecific T-cell engager antibody |
| Manufacturer | Merck & Co. | Genentech, Inc. |
Efficacy
Keytruda (Pembrolizumab) Efficacy in Lymphoma
Keytruda, known generically as pembrolizumab, is a monoclonal antibody that has shown efficacy in the treatment of various types of cancer, including lymphoma. Specifically, it has been used to treat Hodgkin lymphoma (HL) after failure of other treatments. Pembrolizumab works by blocking the programmed death receptor-1 (PD-1) pathway, which is exploited by cancer cells to evade the immune system. By inhibiting this pathway, Keytruda can enhance the body's immune response against cancer cells.
In clinical trials, pembrolizumab has demonstrated significant efficacy in patients with relapsed or refractory classical Hodgkin lymphoma. The overall response rate (ORR) in these studies was notable, with a considerable proportion of patients achieving complete remission. The durability of response has also been a promising aspect of pembrolizumab’s profile, with some patients maintaining remission for extended periods. However, it is important to note that individual responses to treatment can vary, and not all patients with lymphoma will experience the same level of benefit from pembrolizumab.
Lunsumio (Mosunetuzumab-axgb) Efficacy in Lymphoma
Lunsumio, with the generic name mosunetuzumab-axgb, is a bispecific antibody that targets both CD3 on T-cells and CD20 on B-cells. This dual targeting mechanism facilitates the direct killing of B-cells, which is particularly relevant in the treatment of B-cell lymphomas. Mosunetuzumab-axgb has been investigated for its efficacy in non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, among other subtypes.
Recent clinical trials have shown that mosunetuzumab-axgb can induce complete remission in a significant number of patients with relapsed or refractory B-cell lymphomas. The ORR and complete remission rates in these trials have been encouraging, suggesting that mosunetuzumab-axgb may offer a new therapeutic option for patients who have exhausted other treatments. As with pembrolizumab, the responses to mosunetuzumab-axgb can vary, and long-term data on the durability of responses and overall survival are still being collected and analyzed to better understand the full potential of this treatment.
Regulatory Agency Approvals
Keytruda
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Lunsumio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Keytruda or Lunsumio today
If Keytruda or Lunsumio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us